Showing results (101-110 of 141) with videos related to
Sort By:
Pageof 15
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Phase II trial of sorafenib in metastatic thyroid cancerRichard T Kloos, Matthew D Ringel, Michael V Knopp, et al.Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinomaSteven J Cohen, Linus Ho, Sulabha Ranganathan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancerAthanassios Argiris, Austin G Duffy, Shivaani Kummar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang-Min Ning, James L Gulley, Philip M Arlen, et al.Pageof 15